The United Kingdom and the United States have agreed to a key commercial pact that will ensure no tariffs on British pharmaceutical exports entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost expenditure on medicines through the NHS. This pledge guarantees that tariffs on these crucial goods will stay at nothing for a period of the next three years.
This development comes after earlier threats to significantly raise import taxes on patented pharmaceutical products, with figures mentioned as high as 100%.
"This deal between the UK bolsters the global environment for innovative medicines and establishes much-needed equity to American-British drug exports," a release declared.
Commercial Importance
Medicines are one of the the United Kingdom's most significant export categories to the United States, which is easily the largest destination for large British pharmaceutical firms.
Export figures show that in the 12 months prior to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This value represented nearly one-fifth of British export trade in that period.
"This guarantee secures jobs, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement includes several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage manufacturers must refund to the NHS to control costs will be restricted at 15%. Last year, rebates were more than 20%.
Recent Tensions
This agreement follows a protracted row between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American consumers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
